RxDoctor Payments Data

Danielle Jaeger

Physician Assistant · Geneva, NENPI 1639592819

Payments from drug & device makers

$829in general payments, 2019–2025

Across 59 payments — averaging $14.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$448
  • Novo Nordisk$81
  • Pfizer$61
  • Lilly USA, LLC$42
  • Otsuka America Pharmaceutical, Inc.$38
  • Biohaven Pharmaceutical Holding Company Ltd.$32
  • plus $127 from 7 others

What the payments were for

  • Food & beverage$829100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$829 in reported general payments places this provider in the 65th percentile of 1,127 physician assistant providers in Nebraska.

See all physician assistant providers in Nebraska

Medicare billing

Part B allowed, 2024
$7,689
Medicare patients
141
Services billed
202

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide42$44,117
Tresiba Flextouch U-200Insulin Degludec60$36,754
JardianceEmpagliflozin46$28,125
XareltoRivaroxaban41$24,746
FarxigaDapagliflozin Propanediol31$17,722
EliquisApixaban24$17,470
RybelsusSemaglutide12$14,935
TrulicityDulaglutide15$14,190
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,679
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,344
Breo ElliptaFluticasone/Vilanterol20$8,249
Spiriva HandihalerTiotropium Bromide16$8,218
Humalog Kwikpen U-200Insulin Lispro13$6,952
Tresiba Flextouch U-100Insulin Degludec13$6,262
LinzessLinaclotide11$6,022

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$81$59,05254 claims
AstraZenecaFarxiga, Symbicort$16$21,81151 claims
PfizerEliquis$61$17,47024 claims
Lilly USA, LLCTrulicity$42$14,19015 claims
AbbVieLinzess$17$6,02211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,127 physician assistant providers in Nebraska.

Other physician assistant in Geneva

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →